Valeant tanks on short report; 23andMe gets back into health testing;

@FierceBiotech: Novartis inks a string of deals to widen its immuno-oncology arsenal. Article | Follow @FierceBiotech

@JohnCFierce: $AZN's lesinurad is a mess. Safety issues, efficacy ???. Another test for the 'new' FDA. I suspect it gets approved. News | Follow @JohnCFierce

@DamianFierce: $BIIB things I forgot to mention:U.S. royalties on $RHBBY's ocrelizumab are 13.5% to 24%--STX-100 not affected by fibrosis cuts. | Follow @DamianFierce

> Valeant Pharmaceuticals ($VRX) watched its share price plummet more than 20% on Wednesday as a report from a short seller compounded existing worries about the company's business model. News

> 23andMe resumed offering health information through its consumer-targeting spit tests, working its way back to the market after running into issues with the FDA in 2013. More

> Gilead Sciences ($GILD) provided doses of its early-stage treatment for Ebola virus to a patient in the U.K. through a compassionate access program. Item

Medical Device News

@FierceMedDev: Check out this year's Fierce 15: The new strategic med tech mania sets the stage for 2015's Fierce 15. Feature | Follow @FierceMedDev

@VarunSaxena2: Fierce 15 co. Shockwave Medical aims to deploy energy-delivering balloons in the peripheral and coronary arteries. More | Follow @VarunSaxena2

@EmilyWFierce: Discovery of the day: Former "Daria" director illustrated and directed $PFE's Zoloft sad blob commercials. More | Follow @EmilyWFierce

> American Cancer Society guidelines updated to recommend fewer mammograms. Item

> Rheonix bags $28M for molecular testing platforms. Report

Pharma News

@FiercePharma: Michigan governor urges Perrigo shareholders to reject Mylan's offer. Story | Follow @FiercePharma

@CarlyHFierce: Good news for Allergan: Men want to treat wrinkles. Bad? They're clueless about products. Story | Follow @CarlyHFierce

> Teva mulls $7B stock offering to help fund Allergan generics buy. More

> Clinton urges FDA, FTC to take action against questionable pharma pricing. News

Biotech Research News

> King's College team IDs a gene target for Parkinson's. Report

> Georgetown researchers flag success of pilot Parkinson's drug study. More

> Gene therapy for brain protein boosts memory in aged mice. Article

> RIKEN mouse study sheds new light on depression. Item

> MicroRNA controls tissue-specific PTEN expression in brain cancer. Story

Vaccines News

> Sanofi, Gates Foundation and IDRI team up to improve vaccine development process. News

> Cancer vaccines field sees new player emerge with Gritstone's $102M Series A. More

> Inovio's MERS vaccine could hit PhI before year's end. Story

> CSL to buy back $723M of its shares. Item

> Genocea puts pneumococcal vaccine on back burner following PhII failure. Article

Pharma Marketing News

> Good news for Allergan: Men want to treat wrinkles. Bad? They're clueless about products. Story

> PCSK9 drugmakers go Big Data to ID more eligible patients. Report

> Relypsa, Sanofi marketing teams revved up and waiting for FDA nod on patiromer. Article

> AstraZeneca touts new Russian plant as boon for emerging markets sales. Item

> Angling for more reach with providers, Merck melds Univadis unit with Physicians Interactive. More